Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus platinum-doublet induction followed by surgery or radiotherapy in initially unresectable stage III NSCLC
ChiCTR2400086532Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by West China Hospital of Sichuan University. Primary endpoint: 1-year event-free survival rate. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400086532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086532.